Skip to content
Operation Infinite Justice – Lifestyle
Author:
Aspen Neuroscience , Inc.
Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson’s Disease
June 30, 2026
Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary
June 11, 2026
Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
March 18, 2026
Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease
March 12, 2026